<span item_type="fundamental" item_id="24493cb2d7cb327989339646fe31fe2f" counter_id="ST/US/MXCT" env="prod"></span><span item_type="announcement" item_id="648018384621211905" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 9.651 M, beating the estimate of USD 7.298 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.04, beating the estimate of USD -0.076.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -7.62 M.</p><p></p><h4>Net Loss and Accumulated Deficit</h4><p>MaxCyte, Inc. reported a net loss of - $4.8 million for the three months ended March 31, 2026, with an accumulated deficit of - $266.2 million as of the same date. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h4>Revenue</h4><p>Total revenue for the three months ended March 31, 2026, was $9.7 million, representing a -7% decrease from $10.4 million in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h5>Core Revenue</h5><p>Core revenue decreased by -25% to $6.2 million for the three months ended March 31, 2026, from $8.2 million in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Instrument revenue decreased by -7% to $1.3 million from $1.4 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> PA revenue decreased by -41% to $2.3 million from $3.9 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> License revenue decreased by -17% to $2.1 million from $2.5 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Assay service revenue increased by 32% to $0.2 million from $0.1 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Other service revenue increased by 15% to $0.3 million from $0.3 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h5>Non-core Revenue</h5><p>Non-core revenue, primarily from Strategic Platform License (SPL) milestones and royalties, increased by 60% to $3.4 million for the three months ended March 31, 2026, from $2.1 million in the prior year period. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h5>Geographic Revenue</h5><ul><li>Revenue inside the United States was $6.6 million, down from $8.0 million in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></li><li>Revenue outside the United States was $3.0 million, up from $2.4 million in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></li></ul><h4>Gross Profit</h4><p>Gross profit decreased by -9% to $8.1 million for the three months ended March 31, 2026, compared to $8.9 million in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> The gross margin was 84%, down from 86% in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Cost of goods sold increased by 5% to $1.6 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h4>Operating Expenses</h4><p>Total operating expenses decreased by -33% to $14.3 million for the three months ended March 31, 2026, from $21.2 million in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Research and development expenses decreased by -35% to $3.9 million from $5.9 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Sales and marketing expenses decreased by -40% to $3.4 million from $5.7 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> General and administrative expenses decreased by -30% to $6.0 million from $8.5 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Depreciation and amortization expenses decreased by -4% to $1.0 million from $1.1 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h4>Operating Loss</h4><p>Operating loss improved to - $6.2 million for the three months ended March 31, 2026, from - $12.3 million in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h4>Other Income</h4><p>Interest income decreased by -29% to $1.4 million from $2.0 million. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h4>Cash Flows</h4><p>Net cash used in operating activities was - $8.2 million, an improvement from - $14.4 million in the prior year. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> This was due to a net loss of - $4.8 million, offset by $2.2 million in non-cash expenses, and - $5.6 million in changes in operating assets and liabilities. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Net cash provided by investing activities was $2.7 million, primarily from $28.0 million in maturities of investments, offset by $25.1 million in purchases of investments and $0.2 million for capital expenditures. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> Net cash provided by financing activities was $5,000 from the exercise of stock options. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p><h4>Outlook and Strategy</h4><p>MaxCyte, Inc. expects total revenue to increase as customer programs advance, markets grow, and the installed base under SPL license agreements expands. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> The company anticipates continued growth in PA and instrument sales and licenses to cell therapy customers as preclinical programs move into clinical development and commercialization. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span> MaxCyte also expects to attract new customers due to growth in the cell therapy pipeline and a shift towards non-viral approaches, though revenue may fluctuate due to timing uncertainties. <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1287098/000110465926060290/mxct-20260331x10q.htm"></span></p>

MaxCyte | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 9.651 M